Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
Other Sizes |
|
ln Vivo |
Animals treated with zucloperidol (0.2 and 0.4 mg/kg) showed behavioral pharmacology following acute treatment, which included decreased aggressive behavior but unaltered locomotor activity (0.2 mg/kg). By contrast, a notable rise in immobility coincided with the anti-challenge effect at the maximum dose (0.4 mg/kg). No resistance to zuclopentixol against aggressiveness or locomotor activity was seen following subchronic therapy [1]. When zuclopenthixol (0.7 and 1.4 mg/kg) was administered, MDA levels were considerably higher than when the corresponding controls were used. On the MDA levels in the rat brain, however, there was no distinction between the two dose levels' effects. The administration of 1.4 mg/kg zucloperidol significantly lowered GSH levels in animals when compared with vehicle treatment and zuclopentixol (0.7 mg/kg) therapy, according to post hoc pairwise comparisons of averages between groups (n=12) receiving different dose levels of the drug (P<0.001). Nevertheless, the drug's lesser dosages had no effect on the rats' brains GSH levels. The GSH levels of animals treated with 0.7 or 1.4 mg/kg Zuclopenthixol were considerably greater than those of those treated with SCO. When compared to mice treated with a vehicle, the administration of 0.7 mg/kg Zuclopenthixol dramatically boosted GSHPx activity [2].
|
---|---|
References |
[1]. Manzaneque JM, et al. An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5.
[2]. Khalifa AE, et al. Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. Hum Exp Toxicol. 2004 Aug;23(9):439-45 |
Molecular Formula |
C22H25CLN2OS
|
---|---|
Molecular Weight |
400.965
|
CAS # |
53772-83-1
|
Related CAS # |
trans-Clopenthixol dihydrochloride;58045-22-0;Zuclopenthixol-d4 succinate;1246833-97-5;Zuclopenthixol dihydrochloride;58045-23-1
|
SMILES |
OCCN1CCN(CC/C=C2C3=C(SC4=C\2C=CC=C4)C=CC(Cl)=C3)CC1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~200 mg/mL (~498.80 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.86 mg/mL (7.13 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 28.6 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.86 mg/mL (7.13 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 28.6 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4940 mL | 12.4698 mL | 24.9395 mL | |
5 mM | 0.4988 mL | 2.4940 mL | 4.9879 mL | |
10 mM | 0.2494 mL | 1.2470 mL | 2.4940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.